RXRX vs TGTX: which is the better buy in 2026?
Recursion Pharmaceuticals
NASDAQ:RXRX
Recursion's AI drug discovery platform is real science, but $208M annual cash burn against a $1.9B market cap demands clinical proof soon.
Full RXRX analysisTG Therapeutics, Inc.
NASDAQ:TGTX
BRIUMVI is becoming the default subcutaneous anti-CD20 for MS, and the market still prices it like a one-product also-ran.
Full TGTX analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is RXRX or TGTX the better buy in 2026?
RXRX and TGTX are neck and neck at 90/100 on the Compass right now. The better fit depends on which factors matter most to you.
How does Alexandria compare RXRX and TGTX?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.